保乳术后放疗不增加乳腺癌患者20年心脏死亡率:SweBCGRT随机试验随访
SweBCGRT随机试验纳入1187例T1-2N0乳腺癌患者,随机接受术后切线全乳放疗或不进一步治疗,中位随访20年。左侧放疗心脏平均剂量中位数为3.0 Gy。
要点
- 左侧放疗心脏平均剂量中位数为3.0 Gy,低于2017年队列的1.5 Gy。
核心结论
- 全乳放疗后严重晚期副作用有限,未观察到心脏死亡率增加。
- 卒中死亡率增加可能部分继发于心脏副作用、抗凝治疗并发症或偶然,而非切线全乳放疗的直接副作用。
研究设计与样本
- 随机临床试验SweBCGRT,1991年启动,纳入1187例T1-2 N0乳腺癌患者,随机分入术后切线全乳放疗组或不进一步治疗组。
- 处方剂量为临床靶区48至54 Gy,报告20年随访的生存、死因、发病率及第二恶性肿瘤数据。
- 对157例有可获取CT为基础三维治疗计划(Dicom-RT格式)的患者,推导危及器官剂量体积描述符,并与当代放疗技术治疗队列的剂量体积数据比较。
主要发现
- 对侧乳腺癌和肺癌发生率两组相似。
- 左侧治疗心脏平均剂量中位数(范围)为3.0 Gy(1.1-8.1),2017年治疗患者相应值为1.5 Gy(0.4-6.0)。
关键数值与推荐
- 全乳放疗处方剂量为临床靶区48至54 Gy。
- 左侧放疗心脏平均剂量中位数3.0 Gy(范围1.1-8.1),2017年队列为1.5 Gy(范围0.4-6.0)。
临床怎么用
- 保乳术后全乳放疗时,心脏死亡率未增加,支持其用于T1-2 N0乳腺癌患者。
- 左侧放疗心脏平均剂量中位数为3.0 Gy,可作历史参考,当代技术可达1.5 Gy。
- 卒中死亡率增加需关注,但原因可能非放疗直接效应,应综合评估患者心血管风险。
局限性
- 剂量体积分析仅基于157例有可获取三维治疗计划的患者。
- 卒中死亡率增加的原因可能包括心脏副作用、抗凝治疗并发症或偶然,不能确定为放疗直接效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Radiation therapy (RT) after breast-conserving surgery reduces locoregional recurrences and improves survival but may cause late side effects. The main purpose of this paper was to investigate long-term side effects after whole breast RT in a randomized clinical trial initiated in 1991 and to report dose-volume data based on individual 3-dimensional treatment plans for organs at risk. METHODS AND MATERIALS: The trial included 1187 patients with T1-2 N0 breast cancer randomized to postoperative tangential whole breast RT or no further treatment. The prescription dose to the clinical target volume was 48 to 54 Gy. We present 20-year follow-up on survival, cause of death, morbidity, and later malignancies. For a cohort of patients (n = 157) with accessible computed tomography-based 3-dimensional treatment plans in Dicom-RT format, dose-volume descriptors for organs at risk were derived. In addition, these were compared with dose-volume data for a cohort of patients treated with contemporary RT techniques. RESULTS: The cumulative incidence of cardiac mortality was 12.4% in the control group and 13.0% in the RT group (P = .8). There was an increase in stroke mortality: 3.4% in the control group versus 6.7% in the RT group (P = .018). Incidences of contralateral breast cancer and lung cancer were similar between groups. The median Dmean (range) heart dose for left-sided treatments was 3.0 Gy (1.1-8.1), and the corresponding value for patients treated in 2017 was 1.5 Gy (0.4-6.0). CONCLUSIONS: In this trial, serious late side effects of whole breast RT were limited and less than previously reported in large meta-analyses. We observed no increase in cardiac mortality in irradiated patients. Doses to the heart were a median Dmean of 3.0 Gy for left-sided RT. The observed increase in stroke mortality may partly be secondary to cardiac side effects, complications to anticoagulant treatment, or to chance, rather than a direct side effect of tangential whole breast irradiation.
引用
- Killander F, Wieslander E, Karlsson P, et al. No Increased Cardiac Mortality or Morbidity of Radiation Therapy in Breast Cancer Patients After Breast-Conserving Surgery: 20-Year Follow-up of the Randomized SweBCGRT Trial. Int J Radiat Oncol Biol Phys. 2020. PMID: 32302682. doi:10.1016/j.ijrobp.2020.04.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。